Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 12, 2009

Exact Sciences Closes $8.2M Placement and Inks Deal with Mayo Clinic

  • Exact Sciences secured $8.2 million through a private placement and entered a partnership with Mayo Clinic centered on diagnostics for colorectal cancer. The deal with Mayo Clinic gives Exact licenses to various patents and also consists of a research collaboration.

    Under the license agreement, Exact obtained exclusive rights to intellectual property developed by David Ahlquist, M.D., Mayo Clinic. These patents cover advances in sample processing, analytical testing, and data analysis associated with noninvasive, stool-based DNA screening for colorectal cancer. Exact will make up-front, milestone, and royalty payments to Mayo Clinic and will provide funding for future work in Dr. Ahlquist’s lab.

    According to the R&D arrangement with Dr. Ahlquist’s lab, Exact will initially focus efforts on the company’s colorectal screening test. Exact retains exclusive rights to commercialize any resulting product.



    ♦♦♦
    Related News from Exact Sciences

    Exact Receives $22.65M from Genzyme in Asset Purchase Agreement and Equity Investment (Jan. 28, 2009)
    Sequenom Bids to Pick Up Exact Sciences for $41M (Jan. 12, 2009)
    Exact Sciences Expands License Pact with LabCorp for CRC Screening (Jun. 28, 2007)



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »